At a glance
ClinicalIndex Comparison Record- ✓Age 30 years or older
- ✓Diagnosed with Parkinson's disease
- ✓Experiencing depressive symptoms (sadness, decreased energy, or sleep problems)
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Antidepressants in Parkinson's Disease
In Brief
A Phase 3 clinical trial evaluating paroxetine, venlafaxine, and 1 other intervention for Parkinson Disease and Depression. Completed, enrolled 115 participants across 18 sites in 3 countries.
Detailed Summary
The purpose of this study is to find out if two antidepressant medications, paroxetine and venlafaxine, can help control depression in Parkinson's disease, and if these medications affect the motor symptoms of Parkinson's disease such as tremor, stiffness, slowness, and balance.
Study Details
Timeline
Interventions
Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
an inactive substance